Advertisement

A single-arm phase III study exploring the efficacy and safety of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5 mg), in an Asia-Pacific population

      Abstract

      Objective

      The objective was to evaluate the efficacy and safety of a low-dose levonorgestrel intrauterine system with total content 13.5 mg (average approximately 8 μg/24 h over the first year; LNG-IUS 8; Jaydess®) in an Asia-Pacific population.

      Study design

      An open-label, single-arm phase III study conducted at 25 centers in China, Australia and Korea assessed LNG-IUS 8 use over 3 years in nulliparous and parous women (N=1114) aged 18–40 years with regular menstrual cycles (21–35 days). Primary outcome was pregnancy rate, expressed as the Pearl Index. Secondary outcomes included 3-year cumulative failure rate, treatment-emergent adverse events (TEAEs), discontinuation rate, bleeding profile and placement pain.

      Results

      The full analysis set comprised 925 women (mean age 31.6 years, 6.4% nulliparous). Overall unadjusted Pearl Index was 0.35 (95% confidence interval 0.15–0.70); the 3-year cumulative failure rate was 0.9% (95% confidence interval 0.4–1.9). TEAEs and study drug-related TEAEs were reported in 70.1% and 31.2% of women, respectively. Overall, 27.9% of women discontinued the study, 16.9% due to adverse events. Frequent or prolonged bleeding (World Health Organization criteria) decreased from the first to the twelfth 90-day reference intervals (from 5.0% to 0.7% and from 44.1% to 3.0%, respectively), and the percentage of women with amenorrhea increased over time (from 0.4% to 10.8%). Pain on placement was reported as “none” or “mild” in 91.9% of women.

      Conclusions

      LNG-IUS 8 was an effective and well-tolerated contraceptive method, providing another option for women in the Asia-Pacific region.

      Implications

      In this phase III study, LNG-IUS 8 was shown to be highly effective and well tolerated in an Asia-Pacific population and was not associated with any new or unexpected safety events. LNG-IUS 8 provides another contraceptive option for women in the Asia-Pacific region.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sedgh G.
        • Singh S.
        • Hussain R.
        Intended and unintended pregnancies worldwide in 2012 and recent trends.
        Stud Fam Plan. 2014; 45: 301-314
        • American College of Obstetricians and Gynecologists
        ACOG practice bulletin no. 121: long-acting reversible contraception: implants and intrauterine devices.
        Obstet Gynecol. 2011; 118: 184-196
        • National Institute for Health and Care Excellence
        Long-acting reversible contraception: the effective and appropriate use of long-acting reversible contraception.
        (Available from:) ([Last accessed September 11, 2014])
        • Bayer HealthCare Pharmaceuticals
        Mirena® summary of product characteristics.
        (Available from:) ([Last accessed July 30, 2015])
        • Bayer HealthCare Pharmaceuticals Inc
        Jaydess® summary of product characteristics.
        (Available from:) ([Last accessed August 6, 2015])
        • Nelson A.L.
        • Apter D.
        • Hauck B.
        • Schmelter T.
        • Rybowski S.
        • Rosen K.
        • et al.
        Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial.
        Obstet Gynecol. 2013; 122: 1205-1213
        • Centers for Disease Control and Prevention
        MMWR: sexually transmitted diseases treatment guidelines 2010. RR-12. Atlanta, Georgia.
        (Available from:) ([Last accessed October 21, 2014])
        • Belsey E.M.
        • Machin D.
        • d'Arcangues C.
        The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization special programme of research, development and research training in human reproduction.
        Contraception. 1986; 34: 253-260
        • Brown S.
        • Eisenberg L.
        The best intentions: unintended pregnancy and the well-being of children and families.
        National Academy Press, Washington DC1995
        • Cheng D.
        • Schwarz E.B.
        • Douglas E.
        • Horon I.
        Unintended pregnancy and associated maternal preconception, prenatal and postpartum behaviors.
        Contraception. 2009; 79: 194-198
        • Cleland K.
        • Peipert J.F.
        • Westhoff C.
        • Spear S.
        • Trussell J.
        Family planning as a cost-saving preventive health service.
        N Engl J Med. 2011; 364: e37
        • United Nations
        World contraceptive patterns 2013.
        (Available from:) ([Last accessed February 2, 2015])
        • Gemzell-Danielsson K.
        • Schellschmidt I.
        • Apter D.
        A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena.
        Fertil Steril. 2012; 97: 616-622
        • Nilsson C.G.
        • Luukkainen T.
        • Arko H.
        Endometrial morphology of women using a d-norgestrel-releasing intrauterine device.
        Fertil Steril. 1978; 29: 397-401